EGFR and cancer: As explained above, (i) anti-TfR ADCs with low-molecular anti-cancer drugs distributed via pH-sensitive cleavable linkers and (ii) anti-TfR and anti-EGFR bispecific ADCs with low-molecular anti-cancer drugs are implementable using the current technologies.